Dr. Molly Shoichet, University of Toronto, shares her perspective on discovery and commercialization of new therapies and tools in the regenerative medicine (RM) field. As the first Principal Investigator to be featured in CCRM’s Regenerative Medicine Leadership Series, Dr. Shoichet discusses her work, her take on what’s on the horizon for regenerative medicine and the relationship between academic labs and commercialization agents and how, working together, they can advance knowledge and see RM products make it to market. And if you’re interested, you can watch the previous two installments of the Regenerative Medicine Leadership Series.
How do you overcome the limitations of cell culture to scale-up for commercial applications? To break down the barriers to commercialization of cellular therapies, understanding how to efficiently scale-up cell culture systems in order to produce the necessary amount of cells for therapeutic applications is vital. In Cell Culture with Bioreactors, CCRM’s Dr. Elizabeth Csaszar explains how bioreactors can be used to solve many of the experimental complexities of cell culture that are currently blocking the path to commercialization.
Dr. Michael West founded Geron Corporation and is CEO of BioTime Inc., which is focused on developing an array of research and therapeutic products using human embryonic stem cell technology. Dr. West is passionate about translating technologies from the test tubes to clinical applications and strongly advocates for pluripotent stem cells’ potential to revolutionize modern health care. He explains why in this video.
Michael May, President & CEO of CCRM.
Peter Zandstra, CSO of CCRM.
Gregory Bonfiglio, Chair of CCRM’s Board of Directors.